The complete list of injectable peptides shows just how broad the applications are, and the nasal spray peptides article covers non-injectable delivery methods for those exploring alternatives
The getting started guide provides a comprehensive orientation for those building their first protocol, and the peptide dosing guide covers universal principles that apply regardless of the compound
Perspective Back to Top Injectable medications are revolutionizing the weight loss industry and focusing new attention on obesity as a serious and complex disease process
Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine 104-week trial in 3,297 high-risk T2DM patients showed semaglutide reduced composite MACE by 26% versus placebo establishing cardiovascular benefit for GLP-1 receptor agonists
For time to pregnancy, hazard ratios remained below 1.0 in all groups0.60 (95% CI 0.271.32) for overweight, 0.75 (95% CI 0.501.12) for class I obesity, and 0.91 (95% CI 0.651.29) for class IIIII obesitywith corresponding log-rank tests nonsignificant
